carmustine has been researched along with Breast Neoplasms, Male in 3 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Breast Neoplasms, Male: Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-three patients are alive and breast cancer-free at a median of 947 days (range 661-1730 days) after the start of therapy, including one patient who developed myelodysplastic syndrome 809 days after the start of HDCT." | 2.68 | High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. ( Barón, AE; Bearman, SI; Bolwell, BJ; Cagnoni, PJ; Jones, RB; Mechling, BE; Overmoyer, BA; Purdy, MH; Ronk, B; Ross, M; Shpall, EJ; Taylor, CW, 1997) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bearman, SI | 2 |
| Overmoyer, BA | 1 |
| Bolwell, BJ | 1 |
| Taylor, CW | 1 |
| Shpall, EJ | 2 |
| Cagnoni, PJ | 2 |
| Mechling, BE | 1 |
| Ronk, B | 1 |
| Barón, AE | 1 |
| Purdy, MH | 1 |
| Ross, M | 1 |
| Jones, RB | 2 |
| Nieto, Y | 1 |
| Xu, X | 1 |
| Murphy, J | 1 |
| Vredenburgh, J | 1 |
| Chao, NJ | 1 |
| Cao, TM | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, KE | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Taylor, TL | 1 |
| Rizk, NW | 1 |
| Wong, RM | 1 |
| Blume, KG | 1 |
| Hu, WW | 1 |
1 trial available for carmustine and Breast Neoplasms, Male
| Article | Year |
|---|---|
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 1997 |
2 other studies available for carmustine and Breast Neoplasms, Male
| Article | Year |
|---|---|
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1999 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |